Core Viewpoint - The announcement of the Nobel Prize in Physiology or Medicine is expected to stimulate the development of Treg cell therapy and innovative drug research, benefiting companies like HAPO Pharmaceuticals [1] Company Summary - HAPO Pharmaceuticals-B (02142) saw its stock price rise over 8% in early trading, currently up 6.3% at HKD 16.36, with a trading volume of HKD 58.26 million [1] - The company is developing a next-generation antibody HBM4003 targeting the CTLA-4 pathway, which has shown excellent safety characteristics in clinical studies and demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - HAPO's antibody HBM1022, targeting the CCR8 pathway, is considered a highly promising candidate in its pipeline, potentially leading to breakthroughs in tumor immunotherapy [1]
和铂医药-B早盘涨超8% 诺奖聚焦外周免疫耐受 市场关注Treg细胞疗法潜力